Cerebral salt wasting syndrome

Abstract

Traumatic brain injury (TBI) is on the rise, especially in today’s fast-paced world. TBI requires not only neurosurgical expertise but also neurointensivist involvement for a better outcome. Disturbances of sodium balance are common in patients with brain injury, as the central nervous system plays a major role in sodium regulation. Hyponatraemia, defined as serum sodium <135 meq/L is commonly seen and is especially deleterious as it can contribute to cerebral oedema in these patients. Syndrome of inappropriate antidiuretic hormone secretion (SIADH), is the most well-known cause of hyponatraemia in this subset of patients. Cerebral Salt Wasting Syndrome (CSWS), leading to renal sodium loss is an important cause of hyponatraemia in patients with TBI. Although incompletely studied, decreased renal sympathetic responses and cerebral natriuretic factors play a role in the pathogenesis of CSWS. Maintaining a positive sodium balance and adequate hydration can help in the treatment. It is important to differentiate between SIADH and CSWS when trying to ascertain a case for patients with acute brain injury, as the treatment of the two are diametrically opposite.

Keywords

Brain natriuretic peptide - cerebral salt wasting - conivaptan - fludrocortisone - hypertonic saline - hyponatraemia

• REFERENCES

• 1 Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-8
• 2 Bradshaw K, Smith M. Disorders of sodium balance after brain injury. Continuing Education in Anaesthesia, Critical Care & Pain. Vol. 8. 2008
• 3 Powell KR, Sugarman LI, Eskenazi AE, Woodin KA, Kays MA, McCormick KL. et al. Normalization of plasma arginine vasopressin concentrations when children with meningitis are given maintenance plus replacement fluid therapy. J Pediatr 1990; 117: 515-22
• 4 Weidmann P, Hasler L, Gnädinger MP, Lang RE, Uehlinger DE, Shaw S. et al. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 1986; 77: 734-42
• 5 Vespa P. Cerebral salt wasting after traumatic brain injury: An important critical care treatment issue. J Surneu 2007; 69: 230-2
• 6 Peters JP, Welt LG, Sims EA, Orloff J, Needham J. A salt-wasting syndrome associated with cerebral disease. Trans Assoc Am Physicians 1950; 63: 57-64
• 7 Leaf A, Bartter FC, Santos RF, Wrong O. Evidence in man that urinary electrolyte loss induced by pitressin is a function of water retention. J Clin Invest 1953; 32: 868-78
• 8 Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957; 23: 529-42
• 9 Nelson PB, Seif SM, Maroon JC, Robinson AG. Hyponatremia in intracranial disease: Perhaps not the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Neurosurg 1981; 55: 938-41
• 10 Samuels MA. The brain-heart connection. Circulation 2007; 116: 77-84
• 11 Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 1987; 326: 697-8
• 12 Dillingham MA, Anderson RJ. Inhibition of vasopressin action by atrial natriuretic factor. Science 1986; 231: 1572-3
• 13 Lee YJ, Lin SR, Shin SJ, Lai YH, Lin YT, Tsai JH. Brain natriuretic peptide is synthesized in the human adrenal medulla and its messenger ribonucleic acid expression along with that of atrial natriuretic peptide are enhanced in patients with primary aldosteronism. J Clin Endocrinol Metab 1994; 79: 1476-82
• 14 Cerdà-Esteve M, Cuadrado-Godia E, Chillaron JJ, Pont-Sunyer C, Cucurella G, Fernández M. et al. Cerebral salt wasting syndrome: Review. Eur J Intern Med 2008; 19: 249-54
• 15 DiBona GF. Neural control of the kidney: Functionally specific renal sympathetic nerve fibers. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1517-24
• 16 Duggal AK, Yadav P, Agarwal AK, Rewari BB. Clinical approach to altered serum sodium levels. JIACM 2006; 7: 91-103
• 17 Sahay M, Sahay R. Hyponatremia: A practical approach. Indian J Endocrinol Metab 2014; 18: 760-71
• 18 Sherlock M, O'Sullivan E, Agha A, Behan LA, Owens D, Finucane F. et al. Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients. Postgrad Med J 2009; 85: 171-5
• 19 Tisdall M, Crocker M, Watkiss J, Smith M. Disturbances of sodium in critically ill adult neurologic patients: A clinical review. J Neurosurg Anesthesiol 2006; 18: 57-63
• 20 Moritz ML. Syndrome of inappropriate antidiuresis and cerebral salt wasting syndrome: Are they different and does it matter?. Pediatr Nephrol 2012; 27: 689-93
• 21 Maesaka JK, Miyawaki N, Palaia T, Fishbane S, Durham JH. Renal salt wasting without cerebral disease: Diagnostic value of urate determinations in hyponatremia. Kidney Int 2007; 71: 822-6
• 22 Carlotti AP, Bohn D, Rutka JT, Singh S, Berry WA, Sharman A. et al. A method to estimate urinary electrolyte excretion in patients at risk for developing cerebral salt wasting. J Neurosurg 2001; 95: 420-4
• 23 Wijdicks EF, Vermeulen M, Hijdra A, van Gijn J. Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: Is fluid restriction harmful?. Ann Neurol 1985; 17: 137-40
• 24 Isotani E, Suzuki R, Tomita K, Hokari M, Monma S, Marumo F. et al. Alterations in plasma concentrations of natriuretic peptides and antidiuretic hormone after subarachnoid hemorrhage. Stroke 1994; 25: 2198-203
• 25 Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581-9
• 26 Khanna S, Davis D, Peterson B, Fisher B, Tung H, O'Quigley J, Deutsch R. Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury. Crit Care Med 2000; 28: 1144-51
• 27 Taplin CE, Cowell CT, Silink M, Ambler GR. Fludrocortisone therapy in cerebral salt wasting. Pediatrics 2006; 118: e1904-8
• 28 Singh S, Bohn D, Carlotti AP, Cusimano M, Rutka JT, Halperin ML. Cerebral salt wasting: Truths, fallacies, theories, and challenges. Crit Care Med 2002; 30: 2575-9
• 29 Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 2008; 371: 1624-32
• 30 Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care 2009; 11: 14-9
• 31 Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA. et al. Efficacy and safety of oral conivaptan: A V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91: 2145-52
• 32 Hline SS, Pham PT, Pham PT, Aung MH, Pham PM, Pham PC. Conivaptan: A step forward in the treatment of hyponatremia?. Ther Clin Risk Manag 2008; 4: 315-26
• 33 Annane D, Decaux G, Smith N. Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci 2009; 337: 28-36
• 34 Yee AH, Burns JD, Wijdicks EF. Cerebral salt wasting syndrome: Pathophysiology, diagnosis, and treatment. Neurosurg Clin N Am 2010; 21: 339-52
• 35 Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: What difference?. J Am Soc Nephrol 2008; 19: 194-6